SCHEMBL1316699

SCHEMBL1316699

CC(C)(C)OC(=O)c1ccc(-n2cccn2)cc1N

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.43
LMNA P02545 1/20 0.40
NLRP3 Q96P20 2/20 0.39
SYK P43405 1/20 0.39
MAPT P10636 1/20 0.38
LRRK2 Q5S007 1/20 0.38
TBK1 Q9UHD2 3/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPK1 P28482 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
JAK2 O60674 1/20 0.37
JAK3 P52333 1/20 0.37
NOTUM Q6P988 1/20 0.37
AVPR2 P30518 1/20 0.37
PDK2 Q15119 1/20 0.37
HDAC4 P56524 1/20 0.37
IKBKE Q14164 1/20 0.37
KAT6A Q92794 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27989056 0.88 LRRK2 (0.39) GPR119LMNANLRP3MAPTLRRK2
SCHEMBL5066785 0.83 GPR119 (0.44) GPR119LMNASYKMAPTKDM4E
SCHEMBL1969115 0.82 JAK2 (0.53) LMNANLRP3MAPTKDM4EALDH1A1
SCHEMBL1319047 0.81 GPR119 (0.41) GPR119LMNASYKMAPTALDH1A1
SCHEMBL12121348 0.80 LMNA (0.49) LMNAMAPTLRRK2TBK1KDM4E
SCHEMBL27519236 0.78 KAT6A (0.48) GPR119LMNAMAPTKDM4EALDH1A1
SCHEMBL3369502 0.75 MAPT (0.48) LMNANLRP3MAPTLRRK2TBK1
SCHEMBL6774142 0.73 MAPT (0.51) LMNAMAPTLRRK2KDM4EALDH1A1
SCHEMBL29551344 0.73 HCRTR2 (0.46) GPR119LMNA
SCHEMBL7419149 0.72 JAK2 (0.53) LMNANLRP3MAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492582-B2 N-acyl anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2013-07-23 US disclosed
US-8492582-B2 N-acyl anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2013-07-23 US disclosed
US-20110275797-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2011-11-10 US disclosed
US-20110275797-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2011-11-10 US disclosed
EP-2385036-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF Toyama Chemical Co., Ltd. (JP) 2011-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275797-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF COL14A1, COL2A1, COL1A1 GPR119 2749/4885LMNA 546/4885NLRP3 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.